Research ExplorerPublicationsLoss of FFA2 and FFA3 increases insulin secretion and improv...

Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes

Standard

Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes. / Tang, Cong; Ahmed, Kashan; Gille, Andreas; Lu, Shun; Gröne, Hermann-Josef; Tunaru, Sorin; Offermanns, Stefan.

In: NAT MED, Vol. 21, No. 2, 02.2015, p. 173-7.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Tang, C, Ahmed, K, Gille, A, Lu, S, Gröne, H-J, Tunaru, S & Offermanns, S 2015, 'Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes', NAT MED, vol. 21, no. 2, pp. 173-7. https://doi.org/10.1038/nm.3779

APA

Tang, C., Ahmed, K., Gille, A., Lu, S., Gröne, H-J., Tunaru, S., & Offermanns, S. (2015). Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes. NAT MED, 21(2), 173-7. https://doi.org/10.1038/nm.3779

Vancouver

Tang C, Ahmed K, Gille A, Lu S, Gröne H-J, Tunaru S et al. Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes. NAT MED. 2015 Feb;21(2):173-7. https://doi.org/10.1038/nm.3779

Bibtex

@article{af2126368ab549da9904be7335fdd9eb,
title = "Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes",
abstract = "Type 2 diabetes is a major health problem worldwide, and one of its key features is the inability of elevated glucose to stimulate the release of sufficient amounts of insulin from pancreatic beta cells to maintain normal blood glucose levels. New therapeutic strategies to improve beta cell function are therefore believed to be beneficial. Here we demonstrate that the short-chain fatty acid receptors FFA2 (encoded by FFAR2) and FFA3 (encoded by FFAR3) are expressed in mouse and human pancreatic beta cells and mediate an inhibition of insulin secretion by coupling to Gi-type G proteins. We also provide evidence that mice with dietary-induced obesity and type 2 diabetes, as compared to non-obese control mice, have increased local formation by pancreatic islets of acetate, an endogenous agonist of FFA2 and FFA3, as well as increased systemic levels. This elevation may contribute to the insufficient capacity of beta cells to respond to hyperglycemia in obese states. Indeed, we found that genetic deletion of both receptors, either on the whole-body level or specifically in pancreatic beta cells, leads to greater insulin secretion and a profound improvement of glucose tolerance when mice are on a high-fat diet compared to controls. On the other hand, deletion of Ffar2 and Ffar3 in intestinal cells did not alter glucose tolerance in diabetic animals, suggesting these receptors act in a cell-autonomous manner in beta cells to regulate insulin secretion. In summary, under diabetic conditions elevated acetate acts on FFA2 and FFA3 to inhibit proper glucose-stimulated insulin secretion, and we expect antagonists of FFA2 and FFA3 to improve insulin secretion in type 2 diabetes. ",
keywords = "Animals, Blood Glucose/metabolism, Diabetes Mellitus, Type 2/metabolism, Humans, Insulin/metabolism, Insulin Secretion, Insulin-Secreting Cells/metabolism, Mice, Receptors, Cell Surface/metabolism, Receptors, G-Protein-Coupled/metabolism",
author = "Cong Tang and Kashan Ahmed and Andreas Gille and Shun Lu and Hermann-Josef Gr{\"o}ne and Sorin Tunaru and Stefan Offermanns",
year = "2015",
month = feb,
doi = "10.1038/nm.3779",
language = "English",
volume = "21",
pages = "173--7",
journal = "NAT MED",
issn = "1078-8956",
publisher = "NATURE PUBLISHING GROUP",
number = "2",

}

RIS

TY - JOUR

T1 - Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes

AU - Tang, Cong

AU - Ahmed, Kashan

AU - Gille, Andreas

AU - Lu, Shun

AU - Gröne, Hermann-Josef

AU - Tunaru, Sorin

AU - Offermanns, Stefan

PY - 2015/2

Y1 - 2015/2

N2 - Type 2 diabetes is a major health problem worldwide, and one of its key features is the inability of elevated glucose to stimulate the release of sufficient amounts of insulin from pancreatic beta cells to maintain normal blood glucose levels. New therapeutic strategies to improve beta cell function are therefore believed to be beneficial. Here we demonstrate that the short-chain fatty acid receptors FFA2 (encoded by FFAR2) and FFA3 (encoded by FFAR3) are expressed in mouse and human pancreatic beta cells and mediate an inhibition of insulin secretion by coupling to Gi-type G proteins. We also provide evidence that mice with dietary-induced obesity and type 2 diabetes, as compared to non-obese control mice, have increased local formation by pancreatic islets of acetate, an endogenous agonist of FFA2 and FFA3, as well as increased systemic levels. This elevation may contribute to the insufficient capacity of beta cells to respond to hyperglycemia in obese states. Indeed, we found that genetic deletion of both receptors, either on the whole-body level or specifically in pancreatic beta cells, leads to greater insulin secretion and a profound improvement of glucose tolerance when mice are on a high-fat diet compared to controls. On the other hand, deletion of Ffar2 and Ffar3 in intestinal cells did not alter glucose tolerance in diabetic animals, suggesting these receptors act in a cell-autonomous manner in beta cells to regulate insulin secretion. In summary, under diabetic conditions elevated acetate acts on FFA2 and FFA3 to inhibit proper glucose-stimulated insulin secretion, and we expect antagonists of FFA2 and FFA3 to improve insulin secretion in type 2 diabetes.

AB - Type 2 diabetes is a major health problem worldwide, and one of its key features is the inability of elevated glucose to stimulate the release of sufficient amounts of insulin from pancreatic beta cells to maintain normal blood glucose levels. New therapeutic strategies to improve beta cell function are therefore believed to be beneficial. Here we demonstrate that the short-chain fatty acid receptors FFA2 (encoded by FFAR2) and FFA3 (encoded by FFAR3) are expressed in mouse and human pancreatic beta cells and mediate an inhibition of insulin secretion by coupling to Gi-type G proteins. We also provide evidence that mice with dietary-induced obesity and type 2 diabetes, as compared to non-obese control mice, have increased local formation by pancreatic islets of acetate, an endogenous agonist of FFA2 and FFA3, as well as increased systemic levels. This elevation may contribute to the insufficient capacity of beta cells to respond to hyperglycemia in obese states. Indeed, we found that genetic deletion of both receptors, either on the whole-body level or specifically in pancreatic beta cells, leads to greater insulin secretion and a profound improvement of glucose tolerance when mice are on a high-fat diet compared to controls. On the other hand, deletion of Ffar2 and Ffar3 in intestinal cells did not alter glucose tolerance in diabetic animals, suggesting these receptors act in a cell-autonomous manner in beta cells to regulate insulin secretion. In summary, under diabetic conditions elevated acetate acts on FFA2 and FFA3 to inhibit proper glucose-stimulated insulin secretion, and we expect antagonists of FFA2 and FFA3 to improve insulin secretion in type 2 diabetes.

KW - Animals

KW - Blood Glucose/metabolism

KW - Diabetes Mellitus, Type 2/metabolism

KW - Humans

KW - Insulin/metabolism

KW - Insulin Secretion

KW - Insulin-Secreting Cells/metabolism

KW - Mice

KW - Receptors, Cell Surface/metabolism

KW - Receptors, G-Protein-Coupled/metabolism

U2 - 10.1038/nm.3779

DO - 10.1038/nm.3779

M3 - SCORING: Journal article

C2 - 25581519

VL - 21

SP - 173

EP - 177

JO - NAT MED

JF - NAT MED

SN - 1078-8956

IS - 2

ER -